Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …

Futibatinib (Lytgobi®) is an oral, covalently binding, irreversible inhibitor of fibroblast growth
factor receptor (FGFR) 1–4 that is being developed by Taiho Oncology and Taiho …

Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …

Fibroblast growth factor receptor (FGFR) alterations drive oncogenesis in multiple tumor
types. Here we studied pemigatinib, a selective, potent, oral FGFR1–FGFR3 inhibitor, in the …

Background & Aims In recent years, intrahepatic cholangiocarcinoma (iCCA) has evolved as
a “role model” for precision oncology in gastrointestinal cancers. However, its rarity, paired …

Background Targeted therapies have transformed clinical management of advanced biliary
tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for cancer …

Purpose: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to
approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible …

FGFR inhibitors are approved for the treatment of advanced cholangiocarcinoma harboring
FGFR2 fusions. However, the response rate is moderate, and resistance emerges rapidly …

The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated
cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and …

Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and
an extremely high mortality rate. Here, we performed whole-exome sequencing, RNA …